Clinical Trials Logo

Filter by:
NCT ID: NCT04307589 Completed - Clinical trials for Adults Aged 50 Years and Older

The Impact of Grandchild Care on Physical Activity and Sedentary Behavior in People Aged 50 Years and Over

Start date: September 1, 2021
Phase:
Study type: Observational

Given the widespread provision of grandparental child care, examining its impact on grandparents' energy-expenditure related behaviors in the broader context of health is imperative. The maintenance of functional independence and good quality of life is critical at a more advanced age. It has been put forward that an increased duration, frequency and intensity of physical activity (PA) combined with a restriction of sedentary behavior (SB) is the most important strategy to reduce morbidity risk and to foster health in an aging population. The present study aims to fill a gap in current knowledge on (changes in) caregiving grandparents' PA levels and SB patterns. An observational follow-up study will be conducted to examine and compare both energy-expenditure related behaviors linked to body composition and health-related quality of life among caregiving grandparents, non-caregiving grandparents and non-grandparent peers, both momentarily and over time. This fundamental research aims to provide scientific evidence contributing to the promotion of healthy grandparenting in people on the threshold of old age in modern society.

NCT ID: NCT04307537 Completed - Urethral Stricture Clinical Trials

Post-Operative Imaging After Urethroplasty With Peri-catheter Retrograde Urethrography Or Trial of Voiding With Voiding Cysto-urethrography

POIROT
Start date: January 21, 2020
Phase: Phase 2
Study type: Interventional

After a reconstructive procedure of the urethra, a transurethral catheter is usually left in place to allow adequate healing of the tissues without exposure to urine. After 7-21 days, depending on several variables (e.g. type of reconstruction, stricture etiology, …), removal of the transurethral catheter is foreseen. However, in order to do so, the clinician first wants to objectify whether the urethra has indeed healed sufficiently and therefore he/she can rely on early postoperative imaging. Up until today, there is no clear standard about when and how to do early postoperative imaging and current practices are mainly based on expert opinion and habit. Basically, two strategies can be found amongst different urethroplasty centers: peri-catheter retrograde urethrography (pcRUG) and voiding cysto-urethrography (VCUG). A pcRUG is performed by placing a small caliber tube (e.g. feeding tube 5 Fr) in the meatus urethrae of the patient, next to the transurethral catheter (which remains in place), and injecting contrast alongside the catheter. With a VCUG, contrast is injected through the transurethral catheter, up to the bladder. Thereafter, the catheter is removed and the patient is asked to urinate and thus to pass contrast through the urethra. The primary end-point of this study is to compare 'the rightful decision to maintain the catheter at the time of imaging' between pcRUG only and pcRUG followed by VCUG in a within-patient fashion.

NCT ID: NCT04304534 Completed - Clinical trials for Acute Myocardial Infarction

Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack

PACIFIC-AMI
Start date: June 17, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of a dual antiplatelet therapy (acetylsalicylic acid +/- clopidogrel) in patients following a recent heart attack (myocardial infarction) that happens when a blood vessel in the heart suddenly becomes blocked. BAY 2433334, works by blocking a step of the blood clotting process in our body and thins the blood and is a so called oral FXIa inhibitor.

NCT ID: NCT04304508 Completed - Clinical trials for Acute Non-cardioembolic Ischemic Stroke

Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.

PACIFIC-STROKE
Start date: June 15, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of antiplatelet therapy in patients following a recent non cardioembolic ischemic stroke which occurs when a blood clot that has not formed in the heart travelled to the brain. BAY 2433334, works by blocking a step of the blood clotting process in our body and thins the blood and is a so called oral FXIa inhibitor.

NCT ID: NCT04300621 Completed - Healthy Clinical Trials

A Study of Different Oral Thin Film (S)-Ketamine Formulations for Sublingual Administration in Healthy Participants

Start date: June 19, 2020
Phase: Phase 1
Study type: Interventional

The purpose of the study in healthy participants is to characterize the plasma pharmacokinetic (PK) profile of different single dose Oral Thin Film (OTF) (S)-ketamine formulations administered sublingually.

NCT ID: NCT04300400 Completed - Clinical trials for Overactive Bladder Syndrome

Treatment of the Overactive Bladder Syndrome: A Delphi Study

Start date: October 16, 2018
Phase:
Study type: Observational

Idiopathic overactive bladder syndrome (iOAB) is a prevalent condition in urological practice. The variability in management between specialists and between centers remains high. Even guidelines are not always clear on the treatment management of drug therapy resistant OAB. Standardization in OAB treatment is needed.

NCT ID: NCT04296890 Completed - Clinical trials for Fallopian Tube Cancer

A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

SORAYA
Start date: July 23, 2020
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with platinum-resistant high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of Folate Receptor-Alpha (FRα). Patients will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. All patients will receive single-agent MIRV at 6 mg/kg adjusted ideal body weight administered on Day 1 of every 3-week cycle.

NCT ID: NCT04293861 Completed - Knee Osteoarthritis Clinical Trials

Evaluation of the Evolution of Biological and Imaging Markers of Bone and Cartilage Degradation in Patients With Knee Osteoarthritis Receiving Intra-articular Injections of a Hyaluronan Derivative HYMOVIS®

MOKHA
Start date: April 1, 2015
Phase: N/A
Study type: Interventional

This pilot study MOKHA is aimed to evaluate the beneficial effect of HYMOVIS® on cartilage of patients suffering of knee osteoarthritis as revealed by using scientifically sound, objective measurements of biological and MRI-based imaging markers.

NCT ID: NCT04293198 Completed - Ablation Clinical Trials

Evaluating the Performance of the KODEX-EPD CRyOballoon Occlusion Feature in Patients With Atrial Fibrillation

PROOF
Start date: November 4, 2020
Phase:
Study type: Observational

Prospective, multi-center, non-randomized, open label, double arm study to assess the performance of the KODEX-EPD PV occlusion viewer. This study includes patients with atrial fibrillation who are scheduled to undergo a cryo balloon ablation procedure for their atrial fibrillation.

NCT ID: NCT04293094 Completed - Clinical trials for Advanced Solid Tumors

Study of AMG 650 in Adult Participants With Advanced Solid Tumors

Start date: March 11, 2020
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of AMG 650 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).